Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  PharmaCyte Biotech, Inc.    PMCB

PHARMACYTE BIOTECH, INC.

(PMCB)
  Report
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Otc Bulletin Board - Othe…
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
0.0064(c) 0.0056(c) 0.0058(c) 0.0059(c) 0.006 Last
7 029 021 6 168 636 16 235 687 3 473 996 2 899 135 Volume
+3.23% -12.50% +3.57% +1.72% +1.69% Change
More quotes
Financials (USD)
Sales 2019 - - -
Net income 2019 -4,07 M - -
Net cash position 2019 0,52 M - -
P/E ratio 2019 -11,1x
Yield 2019 -
Sales 2020 - - -
Net income 2020 -3,83 M - -
Net cash position 2020 0,82 M - -
P/E ratio 2020 -8,68x
Yield 2020 -
Capitalization 14,0 M 14,0 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees -
Free-Float 97,7%
More Financials
Company
PharmaCyte Biotech, Inc., formerly Nuvilex, Inc., is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Company's Cell-in-a-Box technology will be used as a platform upon which treatments for various types of cancer, including advanced, inoperable... 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about PHARMACYTE BIOTECH, INC.
10/16PHARMACYTE BIOTECH, INC. : Change in Directors or Principal Officers, Financial ..
AQ
10/05PHARMACYTE BIOTECH : Investigational New Drug Application Placed on Hold by the ..
AQ
09/24PHARMACYTE BIOTECH : Continues to Engage the FDA during 30-Day Comment Period
AQ
09/15PHARMACYTE BIOTECH : Successfully Completes Six-Month Stability Study
AQ
09/11PHARMACYTE BIOTECH : Management's Discussion and Analysis of Financial Condition..
AQ
09/09PHARMACYTE BIOTECH : Successfully Completes Second Container Closure Integrity T..
AQ
08/13PHARMACYTE BIOTECH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
08/06PHARMACYTE BIOTECH : FDA Formally Accepts PharmaCyte Biotech's Drug Master File ..
AQ
08/03PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FD..
GL
07/29PHARMACYTE BIOTECH : Receives CE Mark for Licensed COVID-19 Molecular Tests
PU
07/28PHARMACYTE BIOTECH : Announces Submission of Drug Master File to FDA for Company..
AQ
06/29PharmaCyte Biotech's COVID-19 Test Offers “Pool Testing” Dr. Fauc..
GL
06/11PHARMACYTE BIOTECH : Successfully Develops 'Change History' for its Clinical Tri..
AQ
05/06PHARMACYTE BIOTECH : Receives Medical Devices Registration and Submits Pre-EUA A..
PU
05/04PHARMACYTE BIOTECH : Completes Medical Manual for IND Filing
PU
More news
News in other languages on PHARMACYTE BIOTECH, INC.

- No features available -

More news
Chart PHARMACYTE BIOTECH, INC.
Duration : Period :
PharmaCyte Biotech, Inc. Technical Analysis Chart | PMCB | US71715X1046 | MarketScreener
Technical analysis trends PHARMACYTE BIOTECH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers
NameTitle
Kenneth L. Waggoner Chairman, President, CEO & Secretary
Carlos A. Trujillo Chief Financial Officer & Director
Walter H. Günzburgs Chief Scientific Officer
Linda S. Sher Chief Medical Officer
José L. Iglesias Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PHARMACYTE BIOTECH, INC.-85.43%14
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555